Literature DB >> 28062672

Repurposing Antiestrogens for Tumor Immunotherapy.

Thomas Welte1, Xiang H-F Zhang1, Jeffrey M Rosen2.   

Abstract

Svoronos and colleagues observed estrogen receptor alpha-positive cells in the tumor stroma of patients with ovarian cancer that appeared to be independent of both the tumor's estrogen receptor status and tumor type. These cells were identified as immunosuppressive myeloid-derived suppressor cells (MDSC) and could be targeted by antiestrogen therapy, thereby leading to the hypothesis that endocrine therapy when combined with immunotherapy may provide a potential therapeutic benefit by helping to reduce immunosuppressive MDSCs. Cancer Discov; 7(1); 17-9. ©2017 AACRSee related article by Svoronos et al., 72. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28062672      PMCID: PMC5224927          DOI: 10.1158/2159-8290.CD-16-1308

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  9 in total

1.  Regulation of hematopoietic progenitors by estrogens as a basis for new antileukemic strategies.

Authors:  Abel Sánchez-Aguilera; Simón Méndez-Ferrer
Journal:  Mol Cell Oncol       Date:  2015-02-03

Review 2.  The immune system and inflammation in breast cancer.

Authors:  Xinguo Jiang; David J Shapiro
Journal:  Mol Cell Endocrinol       Date:  2013-06-19       Impact factor: 4.102

Review 3.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 4.  Mechanisms of endocrine resistance in breast cancer.

Authors:  C Kent Osborne; Rachel Schiff
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

5.  Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3.

Authors:  L H Wang; X Y Yang; K Mihalic; W Xiao; D Li; W L Farrar
Journal:  J Biol Chem       Date:  2001-06-27       Impact factor: 5.157

6.  Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Authors:  Nikolaos Svoronos; Alfredo Perales-Puchalt; Michael J Allegrezza; Melanie R Rutkowski; Kyle K Payne; Amelia J Tesone; Jenny M Nguyen; Tyler J Curiel; Mark G Cadungog; Sunil Singhal; Evgeniy B Eruslanov; Paul Zhang; Julia Tchou; Rugang Zhang; Jose R Conejo-Garcia
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

7.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.

Authors:  Thomas Welte; Samuel S M Zhang; Tian Wang; Zhiyuan Zhang; David G T Hesslein; Zhinan Yin; Arihiro Kano; Yoshiki Iwamoto; En Li; Joseph E Craft; Alfred L M Bothwell; Erol Fikrig; Pandelakis A Koni; Richard A Flavell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

8.  Myeloid-derived suppressor cells are essential for maintaining feto-maternal immunotolerance via STAT3 signaling in mice.

Authors:  Ting Pan; Yufeng Liu; Li Mei Zhong; Mao Hua Shi; Xiao Bing Duan; Kang Wu; Qiong Yang; Chao Liu; Jian Yang Wei; Xing Ru Ma; Kun Shi; Hui Zhang; Jie Zhou
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

Review 9.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

  9 in total
  5 in total

1.  Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.

Authors:  Diana C Márquez-Garbán; Gang Deng; Begonya Comin-Anduix; Alejandro J Garcia; Yanpeng Xing; Hsiao-Wang Chen; Gardenia Cheung-Lau; Nalo Hamilton; Michael E Jung; Richard J Pietras
Journal:  J Steroid Biochem Mol Biol       Date:  2019-06-19       Impact factor: 4.292

Review 2.  Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.

Authors:  Viroj Boonyaratanakornkit; Nalo Hamilton; Diana C Márquez-Garbán; Prangwan Pateetin; Eileen M McGowan; Richard J Pietras
Journal:  Mol Cell Endocrinol       Date:  2017-11-14       Impact factor: 4.102

Review 3.  The Role of the Estrogen Pathway in the Tumor Microenvironment.

Authors:  Natalie J Rothenberger; Ashwin Somasundaram; Laura P Stabile
Journal:  Int J Mol Sci       Date:  2018-02-19       Impact factor: 5.923

Review 4.  Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.

Authors:  Rama Soundararajan; Jared J Fradette; Jessica M Konen; Stacy Moulder; Xiang Zhang; Don L Gibbons; Navin Varadarajan; Ignacio I Wistuba; Debasish Tripathy; Chantale Bernatchez; Lauren A Byers; Jeffrey T Chang; Alejandro Contreras; Bora Lim; Edwin Roger Parra; Emily B Roarty; Jing Wang; Fei Yang; Michelle Barton; Jeffrey M Rosen; Sendurai A Mani
Journal:  Cancers (Basel)       Date:  2019-05-24       Impact factor: 6.639

Review 5.  TIME Is a Great Healer-Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes.

Authors:  Swarnima Singh; Xiang H F Zhang; Jeffrey M Rosen
Journal:  Cells       Date:  2020-12-23       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.